source
- Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s PatientsCognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
- FDA clears Medtronic's MiniMed Fit tubeless insulin pumpMiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…